2m 2m 2m 2m 2m 2m 2m
DIAMEDICA THERAP (DMAC)
NASDAQ
$6.46+$0.18 (+2.93%)
Price as of Jun 23, 2026 7:54 PM EDT- $317.4MMarket Cap
- 68.36%1-Year Change
- BiotechnologyIndustry
DIAMEDICA THERAP (DMAC)
$6.46+$0.18 (+2.93%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -24.6M +29.16% | -19.1M +45.36% | -13.1M +67.24% | -7.8M -10.56% | |
Depreciation and Amortization Expense | 43,000 +10.26% | 39,000 +30.00% | 30,000 +20.00% | 25,000 +4.17% | |
Total Operating Expenses | 34.4M +28.92% | 26.7M +25.46% | 21.3M +51.90% | 14.0M +2.60% | |
Operating Profit | -34.4M +28.92% | -26.7M +25.46% | -21.3M +51.90% | -14.0M +2.60% | |
Interest Income | 1.7M -27.47% | 2.3M N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 1.7M -27.47% | 2.3M N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 1.7M -26.82% | 2.3M +17.52% | 1.9M +446.46% | 353,000 +330.49% | |
Income before Taxes | -32.7M +34.10% | -24.4M +26.25% | -19.3M +41.69% | -13.6M +0.62% | |
Income Taxes | 28,000 -6.67% | 30,000 -30.23% | 43,000 +53.57% | 28,000 0.00% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -32.8M +34.05% | -24.4M +26.12% | -19.4M +41.72% | -13.7M +0.62% | |
Net Income from Continuing Operations Applicable to Common | -32.7M +34.10% | -24.4M +26.25% | -19.3M +41.69% | -13.6M +0.62% | |
Basic EPS and Net Income | -0.70 +16.67% | -0.60 0.00% | -0.60 +15.38% | -0.52 -20.00% | |
Diluted EPS and Net Income | -0.70 +16.67% | -0.60 0.00% | -0.60 +15.38% | -0.52 -20.00% | |
Basic Weighted Average Shares | 47.0M +16.28% | 40.4M +24.07% | 32.6M +23.16% | 26.4M +27.29% | |
Diluted Weighted Average Shares | 47.0M +16.28% | 40.4M +24.07% | 32.6M +23.16% | 26.4M +27.29% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 15.6M +417.26% | 3.0M -33.41% | 4.5M -3.91% | 4.7M +0.45% | |
Short-Term Investments | 44.2M +7.59% | 41.1M -14.95% | 48.4M +68.04% | 28.8M -28.79% | |
Cash and Cash Equivalents and Short-Term Investments | 59.9M +35.66% | 44.1M -16.54% | 52.9M +57.89% | 33.5M -25.74% | |
Total Current Assets | 60.6M +35.91% | 44.6M -16.89% | 53.7M +58.64% | 33.8M -25.54% | |
Accumulated Depreciation | 150,000 +31.58% | 114,000 +14.00% | 100,000 +25.00% | 80,000 +19.40% | |
Property and Plant and Equipment and Net | 145,000 -2.03% | 148,000 +12.98% | 131,000 -3.68% | 136,000 +94.29% | |
Total Long-Term Assets | 742,000 -57.23% | 1.7M +257.73% | 485,000 -13.39% | 560,000 +400.00% | |
Total Assets | 61.4M +32.42% | 46.3M -14.43% | 54.2M +57.46% | 34.4M -24.49% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 5.1M -4.79% | 5.4M +93.47% | 2.8M +28.51% | 2.2M +42.26% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 128,000 -45.99% | 237,000 -25.24% | 317,000 -20.75% | 400,000 +13,233.33% | |
Total Liabilities | 5.3M -6.39% | 5.6M +81.01% | 3.1M +42.82% | 2.2M +42.52% | |
Retained Earnings | -172.8M +23.40% | -140.0M +21.15% | -115.6M +20.15% | -96.2M +16.58% | |
Total Stockholders Equity | 56.1M +37.80% | 40.7M -20.25% | 51.1M +60.42% | 31.8M -27.71% | |
Total Shares Outstanding | 53.7M +25.51% | 42.8M +12.81% | 38.0M +43.55% | 26.4M 0.00% | |
Cash Flow | |||||
Cash from Operating Activities | -29.1M +31.65% | -22.1M +17.88% | -18.7M +62.70% | -11.5M -6.05% | |
Capital Expenditures | 40,000 +60.00% | 25,000 +4.17% | 24,000 -70.37% | 81,000 +268.18% | |
Cash from Investing Activities | -2.2M -125.60% | 8.6M +146.80% | -18.3M -258.60% | 11.5M +156.18% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 43.9M +265.82% | 12.0M -67.44% | 36.8M +614,133.33% | -6,000 -100.02% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -60.84% +25.07% | -48.64% +11.13% | -43.77% +27.94% | -34.21% -7.31% | |
Return on Equity | -67.68% +27.05% | -53.27% +13.90% | -46.77% +29.69% | -36.06% -7.09% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 11.81 +42.74% | 8.28 -57.04% | 19.27 +23.45% | 15.61 -47.66% | |
Cash Ratio | 3.05 +443.28% | 0.56 -65.59% | 1.63 -25.22% | 2.18 -29.39% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow